checkAd

     538  0 Kommentare Novartis exercises exclusive option agreement with Conatus for the treatment of NASH - Seite 4

    About Novartis
    Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

    Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
    For Novartis multimedia content, please visit www.novartis.com/news/media-library
    For questions about the site or required registration, please contact media.relations@novartis.com

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Novartis AG!
    Long
    86,78€
    Basispreis
    0,67
    Ask
    × 14,19
    Hebel
    Short
    100,07€
    Basispreis
    0,78
    Ask
    × 12,19
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    References
    [1] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. Gastroenterology; 2011:141 (4):e22-e23.
    [2] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. 
    [3] Banini BA, et al. Abstract #46. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 14-19, 2016; Las Vegas, NV.

    # # #

    Novartis Media Relations
    Central media line: +41 61 324 2200
    E-mail: media.relations@novartis.com

    Eric Althoff
    Novartis Global Media Relations
    +41 61 324 7999 (direct)
    +41 79 593 4202 (mobile)
    eric.althoff@novartis.com
    Bhavin Vaid
    Novartis Global Pharma Communications
    +41 61 324 8175 (direct)
    +41 79 792 7510 (mobile)
    bhavin.vaid@novartis.com

    Novartis Investor Relations
    Central investor relations line: +41 61 324 7944
    E-mail: investor.relations@novartis.com

    Central   North America  
    Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
    Pierre-Michel Bringer +41 61 324 1065    
    Thomas Hungerbuehler +41 61 324 8425    
    Isabella Zinck +41 61 324 7188    
    Seite 4 von 5


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Novartis exercises exclusive option agreement with Conatus for the treatment of NASH - Seite 4 Novartis International AG / Novartis exercises exclusive option agreement with Conatus for the treatment of NASH . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer